For research use only
| Cat No. | ABC-X0315C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Fibroblast |
| Species | Human |
| Host Cell | NIH/3T3 |
| Source Organ | Embryo |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The ERBB2 (V773M) NIH/3T3 Cell Line supports investigation of HER2 mutations associated with oncogenic signaling and resistance to HER2-targeted therapies.
Human ERBB2 (V773M) NIH/3T3 Overexpression Cell Line is a genetically engineered model derived from NIH/3T3 mouse fibroblast cells based on customers’ requirement. The cell line stably expresses the human ERBB2 (V773M) mutant via lentiviral-mediated integration. Engineered cells are maintained under low passage conditions (<P20), and expression is validated at the gene level using qRT-PCR. Target ERBB2, also known as HER2, is a member of the EGFR family of receptor tyrosine kinases. The V773M mutation resides in the kinase domain and has been implicated in aberrant signaling in various cancers, including breast and gastric cancer. This alteration can enhance ligand-independent dimerization and downstream PI3K/AKT and MAPK pathway activation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0315C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Embryo |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | NIH/3T3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell line is a useful model for evaluating oncogenic signaling driven by ERBB2 (V773M) and assessing sensitivity to HER2-targeted agents, including small-molecule inhibitors and monoclonal antibodies. It enables mechanistic studies and drug discovery related to HER2-driven malignancies.